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Abstract 
A study has been carried out of the volatile organic compounds present in the exhaled breath 
of 58 cystic fibrosis (CF) patients. An important observation is that the acetic acid vapour 
concentration measured by selected ion flow tube mass spectrometry, SIFT-MS, is 
significantly elevated in the exhaled breath of CF patients, independent of the Pseudomonas 
aeruginosa (PA) infection status (PA-infected median 170 ppbv; PA-negative median 182 
ppbv), compared to that of healthy controls (median 48 ppbv). The cause for this may be 
decreased pH of the mucus lining the CF airways. Thus, we speculate that non-invasive 
measurement of breath acetic acid concentration could serve as an indicator of the acidity of 
the CF airways mucosa. 
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Introduction 
Exhaled breath analysis as a potential non-invasive support to clinical diagnosis and 
therapeutic monitoring is a growing area of research that is showing great promise. In this 
regard, the search is on for volatile metabolites that are reliable indicators of respiratory 
infection and systemic disease. The relevant metabolites are mostly volatile organic 
compounds, VOCs, but also include some inorganic compounds such as nitric oxide and 
ammonia. [1]. Selected ion flow tube mass spectrometry, SIFT-MS (see concise overviews in 
[2-4]), allows the analysis of exhaled breath to be accomplished both in real time and on-line 
in single breath exhalations or of breath samples collected into bags for off-line analysis. 
Using SIFT-MS breath analysis has been accomplished of significantly large cohorts of 
healthy controls and thus the establishment of reference ranges of the most common breath 
metabolites have been achieved [5].  
A particular aspect of SIFT-MS breath analysis research is directed towards identification of 
volatile biomarkers of respiratory bacteria. Much effort has been given to Pseudomonas 
aeruginosa (PA) that commonly infect the lungs of cystic fibrosis (CF) patients, which has 
involved detailed studies of in vitro cultures of PA, including many genetically identified 
strains and their biofilm or planktonic modes of growth. This work, over a decade, has 
resulted in the establishment of hydrogen cyanide, HCN, as a volatile biomarker of PA [6-9]. 
Most recently, a multi-centre study involving 8 UK hospitals has quantified HCN in the 
exhaled breath of 233 children with CF and demonstrates that HCN is indeed a discreet 
specific (albeit not yet entirely sensitive) biomarker of PA. The exciting results of this 
SPACE study are reported recently in ERJ Open Research [10]. 
The pathology of CF is well documented. It is a genetically inherited, life-shortening chronic 
illness associated with excessive abnormal mucus production in the airways and breathing 
becomes increasingly difficult. The lungs then become a rich nutrient medium for 
opportunistic pathogens that are normally harmless for healthy people but cannot be removed 
fast enough in CF thus encouraging chronic respiratory infections such as PA, 
Staphylococcus aureus (SA) [11, 12] and Burkholderia cepacia [13, 14] and the fungus 
Aspergillus fumigatus (AF) [15]. Currently, the detection of these pathogens in the airways is 
achieved by culturing sputum samples, but CF children have difficulty in expectorating 
sputum; hence the attraction of non-invasive breath analysis to detect volatile compound 
biomarkers of specific pathogens.  
Continuing with this research, we have carried out a study of the VOCs in the exhaled breath 
of two groups of CF patients, one whose airways are infected with PA and those who are PA 
negative. The major question posed was whether or not other volatile compounds in the 
breath, other than HCN, can be used to distinguish between these CF patient groups. The 
detailed results of this wider study will be published in an upcoming paper (Španěl et. al., in 
preparation). However, the focus of the present note is to report the serendipitous observation 
of greatly elevated absolute concentrations of acetic acid vapour in the exhaled breath of the 
CF patients compared to those measured for healthy persons. This surprising and unexpected 
observation may have relevance to the physiology in CF and its clinical treatment. This note 
thus presents the detailed experimental data for acetic acid and compares these results with 
the results for healthy cohorts, and briefly discusses the origin of the acetic acid and its 
implications in CF. 
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Materials and methods 
Subjects 
A total of 58 patients with CF (26 males and 32 females, age range 2-41 years, median 14 
years) were recruited at the Prague Motol University Hospital. Of these, 38 were assessed as 
PA negative and 20 were infected with PA (according to a positive result of a PCR test, in 18 
patients the diagnosis was confirmed by cultivation). The study was approved by the 
institutional ethics committee and the patients or their legal guardians provided an 
appropriate written consent.  
Breath analysis. 
Mixed expiratory breath samples were collected in the morning (before 12:00) during regular 
visits by the patients to the CF clinic. Each patient was asked to slowly inflate a 4 L 
disposable Nalophan bag through an 8 cm long PTFE tube (1/4 inch OD, 0.23 inch ID), 
which requires several exhalations. The typical flow rate was about 100mL/s as restricted by 
the ID of the PTFE tube. The sample bags were then immediately placed into a temperature 
controlled enclosure held at 37⁰C and coupled to the SIFT-MS instrument via a heated 
calibrated capillary. The instrument was operated in the multiple ion monitoring mode to 
acquire the count rates of the reagent and analyte ions at all integral values of m/z within the 
range 10 to 120. Analysis was performed within 20 minutes to avoid diffusive losses through 
the bag material, although previous studies have shown that such losses are not significant for 
wide-ranging compound types over a storage period of 24 hours. (see [16]). The room air was 
routinely analysed prior to coupling the sample bag to the SIFT-MS instrument. For GC-MS 
analysis of the same sample, an SPME fibre was inserted into the bag for 30 min at the 
enclosure temperature of 37⁰C.  
 
SIFT-MS quantification and identification of acetic acid  
Both positive identification and accurate quantification of volatile metabolites in breath is 
essential for their concentrations to be used as disease biomarkers. Thus, for SIFT-MS 
analysis of any trace compound present in humid exhaled breath, it is important to understand 
the underpinning ion chemistry. The principles and operation of SIFT-MS need not be 
described in detail here, since they are well established [2, 3, 17, 18]. It is sufficient to say 
that SIFT-MS exploits controlled chemical ionization of trace compounds in air/breath 
samples by the reagent ions H3O+, NO+ and O2+•, either individually or in combinations, in a 
helium-buffered flow tube and the characteristic analyte ions produced are identified and 
counted by the downstream analytical mass spectrometer/detection system. Concentrations of 
the neutral trace analyte molecules in the sample are then calculated [17, 18]. The most 
suitable reagent ion for analyses of acetic acid in the vapour phase is NO+, as has been 
established in previous studies [19-21]. NO+ (m/z 30) reacts with CH3COOH under SIFT-MS 
reactor conditions to form an analyte adduct ion as follows: 
  NO+ + CH3COOH + He → NO+.CH3COOH + He 
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The helium atom acts only as a mediator to stabilise the excited adduct analyte ion 
(NO+.CH3COOH)* (m/z 90) against unimolecular dissociation back to the ion/molecule 
reactants. Then the monohydrate of the adduct ion, NO+.CH3COOH.H2O (m/z 108), is 
similarly formed in the presence of water vapour molecules introduced into the helium carrier 
gas of the SIFT-MS reactor when a sample of very humid exhaled breath is being analysed. 
This monohydrate ion must be included as an additional analyte ion in order to obtained 
accurate SIFT-MS analysis of acetic acid. Thus, the acetic acid concentration was calculated 
from the count rates of reagent ions at m/z 30, 48, 66 and analyte ions at m/z 90 and 108. 
What is equally important is that previous work has shown that the ratio of the signal levels 
of the adduct ion (m/z 90) and its monohydrate (m/z 108) at the downstream analytical mass 
spectrometer depends on the water vapour concentration in the breath sample [20], which is 
close to 6% by volume at the donor body temperature (36-37C) and which is routinely 
measured during SIFT-MS analyses [22]. Thus, the measurement of the m/z 108 to (m/z 90 + 
m/z 108) signal ratio acts as an important check on the proper identification of the acetic acid.   
GC-MS confirmation of the presence of acetic acid 
Solid phase microextraction (SPME) was used to identify trace compounds present in these 
bag samples by GC-MS analyses. Carboxene polydimethylsiloxane (CAR/PDMS)-coated 
SPME fibres (Supelco, Bellefonte, PA, USA) were inserted into the bags for 30 min at a 
temperature of 37ºC. The fibres were directly inserted into the injector (heated to 220°C) of 
the GC-MS instrument (FOCUS GC with ITQ 700 ion trap mass spectrometer, Thermo 
Fisher Scientific Inc., USA). The GC oven temperature program was the following: 38°C 
(hold 8 min), 4°C/min ramp up to 100 °C,  30°C/min ramp up to 210 °C, and a final hold 3 
min (total run time 30 min). The GC capillary column used was a TG-624 (Thermo Fisher 
Scientific Inc., USA) with helium carrier gas flow of 1 mL/min. Electron ionisation (70 eV) 
was used to analyse the eluting molecules by the ion trap operating in the scan mode (m/z 15–
400, scan rate 1 scan/s). Peak identification was based on mass spectral interpretation and 
comparisons with the NIST 2.0 library. 
A sample chromatogram and a mass spectrum confirming the presence of acetic acid is 
shown in Figure 1. By this GC-MS and SIFT-MS combined approach we can be confident 
that we are identifying and quantifying correctly the acetic acid in exhaled breath. 
Results  
The present measurements of the acetic acid breath concentrations for all the CF patients 
enrolled into the study are given in Figure 2, as a box-and whisker plot. It is very important to 
note that no significant difference was observed between the breath acetic acid concentrations 
of the PA-infected (median 170, 110-210 ppbv) and the PA-negative groups (median 182; 
IQR 139-336 ppbv).  However, these concentrations are several times greater than end-
expiratory concentration of acetic acid established for the healthy population (median 48 
ppbv, range 20-60 ppbv, see Figure 2). [23]. It is pertinent to note that the concentrations of 
acetic acid present in the ambient air were routinely checked by SIFT-MS analyses of the 
room air and no measurable background was observed. 
Discussion 
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Until recently, acetic acid received little attention as an endogenous compound, but it has 
been known for some time to be present in exhaled breath condensate [24] and saliva [24, 
25]. Acetate, the anionic form of acetic acid in biological fluids, is a physiological metabolite 
involved in normal human biochemistry. Plasma acetate concentrations in healthy people 
usually vary between 50 and 100 μmol l−1 [26]. The partition of acetic acid between the 
gaseous and liquid concentration will be strongly influenced by pH of the solution phase and 
can be estimated according to the Henry’s Law constant for this fatty acid [27]. It turns out 
that for the above acetate concentration and for a pH of the airways mucosa near to 7, the 
exhaled breath concentration of acetic acid should be of the order of 10 parts-per-billion by 
volume ppbv [23].  At lower pH (acidic mucosa) the gas phase (exhaled breath) acetic acid 
will correspondingly be increased. 
The first SIFT-MS analysis of breath  acetic acid followed our research of the ion chemistry 
required for identifying and quantifying the isobaric compounds propanol, methyl formate 
and acetic acid by SIFT-MS [20]. Thus, the ion-molecule kinetics were established for the 
accurate analysis of acetic acid using NO+ reagent ions. In this study the concentration of 
acetic acid in mouth-exhaled breath samples from five healthy volunteers collected into 
Nalophan bags using the same procedure as used in the present study was measured using 
SIFT-MS  and was seen to vary from about 30–60 ppbv and the concentrations in nose-
exhaled breath were about a factor of 2 lower. That the oral cavity is a significant source of 
acetic acid was also demonstrated by analysing the oral cavity static gas after a mouth wash 
with water, when the concentrations reduced to about 10 ppb showing that this compound is 
also partially systemic, i.e., originating at the alveolar interface and/or in the airways mucosa. 
It is worthy  of note that fatty acids have been detected in exhaled breath from healthy 
persons by direct analysis using electrospray ionization and atmospheric pressure ionization-
mass spectrometry [28, 29] A further relevant observation is that when analysing the exhaled 
breath of a very limited cohort of patients with lung tumours by SIFT-MS, it was observed 
that breath acetic acid was elevated above that for breath healthy controls and we tentatively 
argued that this may be because the tissue surrounding the lung tumours was at a lower pH 
than healthy lung tissue [30].  
More relevant to the present results is a previous concerted study to identify potential 
biomarkers in the breath of patients suffering from gastro-oesophageal reflux disease 
(GERD) using both SIFT-MS and GC-MS analysis in parallel to ensure positive 
identification of VOCs [23]. End-expiratory concentration of acetic acid measured by SIFT-
MS in mouth exhaled breath of 22 GERD patients (median 85 ppbv, see Figure 2) was found 
to be significantly higher than that in breath of a control group of 24 healthy persons (median 
48 ppbv). This increase of acetic acid in GERD may be due to locally decreased pH of the 
surface of the airways/trachea. It was concluded that breath acetic acid may be useful for non-
invasive diagnostics of GERD. 
 
However, the present results clearly reveal that breath acetic acid is greatly elevated in CF 
patients above both healthy controls and the GERD patients; the median value is a factor of 2 
higher than those for the GERD patients and about 4 times higher than the healthy group. Yet 
there is acetic acid at the very large concentrations of 1100 ppbv and 1600 ppbv in two of the 
CF patients (see Figure 2); these concentrations which were very thoroughly checked and 
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verified are 30-40 times greater than normal. This is a unique differentiation between healthy 
and the diseased patients as far as breath analysis of volatile biomarkers is concerned and 
deserves a physiological explanation because it may have implications to the diagnosis and 
treatment of CF. 
Since there is no significant difference in breath acetic acid concentration between the PA-
infected and PA-free groups, the conclusion must be that this acid is not produced by the PA 
bacteria. So what is its origin? Is it due to the abnormal mucus congestion in the lungs and 
airways of the CF patients and is the mucus at a low pH (acidic) relative to normal respiratory 
track tissue? If this is so, it would effectively move the equilibrium from liquid phase acetate 
ions (non-volatile) to gas phase acetic acid molecules (volatile).  
There have been discussions and conflicting ideas as to the pH of the mucosa in the CF lung 
and airways [31], some clinicians suggesting that therapy may be directed toward increasing 
the pH of airways [32]. Our results apparently suggest that the mucosa in CF is acidic given 
the efficient release of acetic acid vapour. Support for an acidic mucosa comes also from a 
recent study of the new-born porcine lung [33] in which it was found that at birth these lungs 
lack infection and inflammation, but have a reduced ability to eradicate bacteria. In the 
healthy pigs the thin layer of airway surface liquid rapidly killed bacteria in vivo. However, it 
was found that the mucosa pH was more acidic in the CF pigs, which inhibited the 
antimicrobial activity of the mucosa. The increased acidity was linked to a channel that 
facilitates HCO3− anion production and impairs the killing of bacteria that enter the newborn 
lung. These findings again indicate that increasing mucosa pH might prevent the initial 
infection in patients with CF.  It is also pertinent to recognise that that the pH of exhaled 
breath condensate was found to be significantly lower in CF subjects (pH 6.6) compared to 
that in a control group (pH 8.1) [34]. 
Conclusion 
The data presented in this note are the first observation and measurement of elevated 
concentrations of acetic acid in the exhaled breath of CF patients. Thus, we speculate that 
breath acetic acid could be a non-invasive biomarker of the acidity of the airways mucosa, 
which could help to assess the risk of bacterial infection and ultimately improve the efficacy 
of CF therapy. It may be that measurement of acetic acid in exhaled breath could support CF 
diagnosis alongside the standard sweat test. Clearly, further work is needed to substantiate 
these findings using greater cohorts of healthy volunteers and CF patients. 
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Figure 1. The GC-MS chromatogram of SPME-extracted volatile compound from a breath sample of one of the CF patients confirming the presence of acetic 
acid by the elution time and the ion fragmentation spectrum. 
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Figure 2 Concentrations of acetic acid in exhaled breath of healthy controls and patients with GERD (from ref. 24) and patients with CF obtained using SIFT-
MS. In addition to the individual data points the box-and-whisker plots are included to indicate the 10th, 25th, 50th, 75th and 90th percentiles. 
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